Achillion Pharmaceuticals (ACHN) : Rtw Investments reduced its stake in Achillion Pharmaceuticals by 5.26% during the most recent quarter end. The investment management company now holds a total of 2,424,136 shares of Achillion Pharmaceuticals which is valued at $21,186,949 after selling 134,723 shares in Achillion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Achillion Pharmaceuticals makes up approximately 6.48% of Rtw Investments’s portfolio.
Other Hedge Funds, Including , Wellington Management Group Llp reduced its stake in ACHN by selling 418,828 shares or 19.06% in the most recent quarter. The Hedge Fund company now holds 1,778,333 shares of ACHN which is valued at $15,542,630.Clinton Group Inc boosted its stake in ACHN in the latest quarter, The investment management firm added 2,821 additional shares and now holds a total of 39,971 shares of Achillion Pharmaceuticals which is valued at $349,347. Achillion Pharmaceuticals makes up approx 0.01% of Clinton Group Inc’s portfolio.Acrospire Investment Management reduced its stake in ACHN by selling 540 shares or 5.35% in the most recent quarter. The Hedge Fund company now holds 9,560 shares of ACHN which is valued at $85,944. Achillion Pharmaceuticals makes up approx 0.06% of Acrospire Investment Management’s portfolio.Turner Investments reduced its stake in ACHN by selling 3,990 shares or 0.46% in the most recent quarter. The Hedge Fund company now holds 855,570 shares of ACHN which is valued at $7,802,798. Achillion Pharmaceuticals makes up approx 2.28% of Turner Investments’s portfolio.Quantbot Technologies Lp reduced its stake in ACHN by selling 2,306 shares or 48.44% in the most recent quarter. The Hedge Fund company now holds 2,455 shares of ACHN which is valued at $21,408.
Achillion Pharmaceuticals closed down -0.03 points or -0.36% at $8.23 with 9,28,170 shares getting traded on Thursday. Post opening the session at $8.26, the shares hit an intraday low of $8.1042 and an intraday high of $8.33 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Achillion Pharmaceuticals reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Chardan Capital Markets Initiated Achillion Pharmaceuticals on Jul 14, 2016 to “Sell”, Price Target of the shares are set at $4.Achillion Pharmaceuticals was Upgraded by JMP Securities to ” Mkt Outperform” on Jul 7, 2016.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.